Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-N188 PET/CT for Nectin-4 Expression in Malignant Tumors
NCT05593107Phase 1Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68 N188 in cancer, sponsored by Peking University First Hospital. Primary endpoint: Diagnostic efficacy of 68Ga-N188 PET/CT at 1 year. Started Aug 2022; status: recruiting.
02
Drugs
gallium Ga 68 N188
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05593107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593107.